Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy

被引：0
|
作者：
Tada, K. [1 ,2 ]
Shoji, H. [3 ]
Kitano, S. [4 ]
Nishimura, T. [5 ]
Shimada, Y. [3 ]
Nagashima, K. [6 ]
Ito, A. [7 ]
Honma, Y. [3 ]
Iwasa, S. [3 ]
Okita, N. [3 ]
Takashima, A. [3 ]
Kato, K. [3 ]
Yamada, Y. [3 ]
Katayama, N. [8 ]
Boku, N. [3 ]
Heike, Y. [1 ]
Hamaguchi, T. [3 ]
机构：
[1] St Lukes Int Hosp, Immunotherapy & Cell Therapy Serv, Tokyo, Japan
[2] Natl Canc Ctr, Div Canc Immunotherapy, Tokyo, Japan
[3] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Tokyo Jikei Med Univ, Gastrointestinal Med Div, Tokyo, Japan
[6] Chiba Univ, Dept Global Clin Res, Chiba, Japan
[7] Natl Canc Ctr, Hematopoietci Stem Cell Transplant Div, Tokyo, Japan
[8] Mie Univ, Dept Hematol & Oncol, Tsu, Mie 514, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30240-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
406
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer
    Chibaudel, B.
    Tournigand, C.
    Bonnetain, F.
    Andre, T.
    Lledo, G.
    Maindrault-Goebel, F.
    Larsen, A. K.
    Louvet, C.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer
    Yamamoto, Seiji
    Fujii, Hironori
    Murayama, Kotaro
    Iihara, Hirotoshi
    Watanabe, Daichi
    Yamada, Yunami
    Kobayashi, Ryo
    Kiyama, Shigeru
    Makiyama, Akitaka
    Urano, Kimihiko
    Matsuhashi, Nobuhisa
    Matsuura, Katsuhiko
    Suzuki, Akio
    ANTICANCER RESEARCH, 2023, 43 (11) : 5099 - 5105
  • [3] Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
    Chibaudel, Benoist
    Bonnetain, Franck
    Tournigand, Christophe
    Bengrine-Lefevre, Leila
    Teixeira, Luis
    Artru, Pascal
    Desrame, Jerome
    Larsen, Annette K.
    Andre, Thierry
    Louvet, Christophe
    de Gramont, Aimery
    ONCOLOGIST, 2011, 16 (09): : 1228 - 1238
  • [4] Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Gerger, Armin
    El-Khoueiry, Anthony
    Zhang, Wu
    Yang, Dongyun
    Singh, Harpreet
    Bohanes, Pierre
    Ning, Yan
    Winder, Thomas
    LaBonte, Melissa J.
    Wilson, Peter M.
    Benhaim, Leonor
    Paez, David
    El-Khoueiry, Rita
    Absenger, Gudrun
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5783 - 5792
  • [5] Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy
    Gerger, A.
    Zhang, W.
    Yang, D.
    Bohanes, P. O.
    Ning, Y.
    Winder, T.
    Labonte, M. J.
    Wilson, P. M.
    Benhaim, L.
    El-Khoueiry, R.
    Absenger, G.
    El-Khoueiry, A. B.
    Iqbal, S.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan- and/or oxaliplatin-based chemotherapy
    Catalano, V.
    D'Emidio, S.
    Loupakis, F.
    Graziano, F.
    Torresi, U.
    Mari, D.
    Bisonni, R.
    Giordani, P.
    Giustini, L.
    Falcone, A.
    Silva, R. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy
    Perez Martelo, M.
    Alvarez Fernandez, J.
    Abdulkader Nallib, I.
    Brozos Vazquez, E.
    Vazquez Rivera, F.
    Vidal Insua, Y.
    Candamio Folgar, S.
    Lopez Lopez, R.
    Ruiz Banobre, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S118 - S119
  • [8] Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
    Hamfjord, J.
    Guren, T. K.
    Dajani, O.
    Johansen, J. S.
    Glimelius, B.
    Sorbye, H.
    Pfeiffe, P.
    Lingjaerde, O. C.
    Tveit, K. M.
    Kure, E. H.
    Pallisgaard, N.
    Spindler, K-L G.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1088 - 1095
  • [9] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    L Paré-Brunet
    A Sebio
    J Salazar
    A Berenguer-Llergo
    E Río
    A Barnadas
    M Baiget
    D Páez
    The Pharmacogenomics Journal, 2015, 15 : 397 - 404
  • [10] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
12345